MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
3.
ErkanDDerksenRLevyR. Antiphospholipid Syndrome Clinical Research Task Force report. Lupus2011; 20: 219–224.
4.
TripodiAChantarangkulVClericiMNegriBGalliMMannucciPM. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. [Comparative Study]. Br J Haematol2001; 115: 672–678.
5.
PengoVTripodiAReberG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. [Practice Guideline]. J Thromb Haemost2009; 7: 1737–1740.
6.
7.
SchulmanSKearonCKakkarAK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med2009; 361: 2342–2352.
8.
BauersachsRBerkowitzSDBrennerB. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med2010; 363: 2499–2510.
9.
SchulmanSKakkarASchellongS. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood [Abstract]2011; 118: Abstract 205.
10.
The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med2012; 366: 1287–1297.
11.
GreenLLawrieASPatelS. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol2010; 151: 469–476.
12.
EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviM. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation2011; 124: 1573–1579.
